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Abstract
Background: Chronic gastro-oesophageal reflux disease and excessive body fat are considered principal causes of 
Barrett's oesophagus (a metaplastic change in the cells lining the oesophagus) and its neoplastic progression, 
oesophageal adenocarcinoma. Metabolic disturbances including altered levels of obesity-related cytokines, chronic 
inflammation and insulin resistance have also been associated with oesophageal cancer development, especially in 
males. Physical activity may have the potential to abrogate metabolic disturbances in males with Barrett's oesophagus 
and elicit beneficial reductions in body fat and gastro-oesophageal reflux symptoms. Thus, exercise may be an effective 
intervention in reducing oesophageal adenocarcinoma risk. However, to date this hypothesis remains untested.
The 'Exercise and the Prevention of Oesophageal Cancer Study' will determine whether 24 weeks of exercise training
will lead to alterations in risk factors or biomarkers for oesophageal adenocarcinoma in males with Barrett's
oesophagus. Our primary outcomes are serum concentrations of leptin, adiponectin, tumour necrosis factor-alpha, C-
reactive protein and interleukin-6 as well as insulin resistance. Body composition, gastro-oesophageal reflux disease
symptoms, cardiovascular fitness and muscular strength will also be assessed as secondary outcomes.
Methods/Design: A randomized controlled trial of 80 overweight or obese, inactive males with Barrett's oesophagus 
will be conducted in Brisbane, Australia. Participants will be randomized to an intervention arm (60 minutes of 
moderate-intensity aerobic and resistance training, five days per week) or a control arm (45 minutes of stretching, five 
days per week) for 24 weeks. Primary and secondary endpoints will be measured at baseline (week 0), midpoint (week 
12) and at the end of the intervention (week 24).
Discussion: Due to the increasing incidence and very high mortality associated with oesophageal adenocarcinoma, 
interventions effective in preventing the progression of Barrett's oesophagus are urgently needed. We propose that 
exercise may be successful in reducing oesophageal adenocarcinoma risk. This primary prevention trial will also 
provide information on whether the protective association between physical activity and cancer is causal.
Trial Registration: ACTRN12609000401257
Background
During the past three decades, the incidence of oesopha-
geal adenocarcinoma (AC) has risen by more than 300%
in females and 500% in males; faster than any other can-
cer in Western Europe, America and Australia [1-5].
Moreover, the incidence of Barrett's oesophagus, the
metaplastic precursor to oesophageal AC (Figure 1), is
also rising [6]. The prognosis for patients with AC is poor
with a 5 year survival rate of 10-15% [7,8].
Chronic reflux of gastric contents into the lower
oesophagus is widely accepted as the primary cause of
Barrett's oesophagus and oesophageal AC [9]. Recent
research has demonstrated that excessive body fat is also
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a cause of oesophageal AC and is likely to act through
promoting neoplastic progression from Barrett's oesoph-
agus [10]. Obesity [body mass index (BMI) > 30 kg/m2] is
a determinant of acid reflux [11], and has been associated
with a two-fold increase in the risk of Barrett's oesopha-
gus [12] and up to a three-fold increase in oesophageal
AC risk [13,14]. Interestingly, the co-occurrence of obe-
sity and frequent reflux symptoms increases a person's
risk of Barrett's oesophagus by over 30-fold [12]. Body fat
distribution also influences Barrett's oesophagus risk.
Central obesity indicated by a waist circumference of > 80
cm has been shown to increase the risk of Barrett's
oesophagus by over two-fold, independent of BMI and
gastro-oesophageal reflux [15,16].
Adipose tissue is a dynamic endocrine organ. Adipo-
cytes secrete numerous hormones or 'adipokines' that
exhibit mitogenic activity such as leptin, adiponectin,
interleukin-6 (IL-6) and tumour necrosis factor-alpha
(TNF-α). It has been postulated that these hormones may
mediate the progression of Barrett's oesophagus to can-
cer (Table 1).
Leptin
The adipokine leptin is secreted by adipocytes and gastric
chief cells and is positively associated with insulin levels,
inflammation and body fat. In vitro, leptin has been
shown to elicit mitogenic [17-19], angiogenic [17,18,20]
and anti-apoptotic [18,19] effects when administered to
oesophageal AC cell lines, enhancing cellular prolifera-
tion. Leptin receptors are also present on oesophageal
epithelial cells providing a pathway for signalling [21]. A
recent epidemiological study reported that male patients
with Barrett's oesophagus had significantly higher leptin
levels than BMI-matched controls, but no such associa-
tion was seen for women [22]. These findings implicate
leptin as a likely candidate mediator driving the progres-
sion from Barrett's oesophagus to oesophageal AC.
Adiponectin
Adiponectin is another adipokine implicated in the bio-
chemical pathways to oesophageal AC development.
Unlike leptin, adiponectin is inversely related to obesity
and has anti-inflammatory and insulin sensitising proper-
ties. Adiponectin circulates as three oligomeric isoforms:
high molecular weight (HMW), medium molecular
weight (MMW) and low molecular weight (LMW) adi-
ponectin. HMW adiponectin may be the major bioactive
form as decreased levels are more closely correlated with
insulin resistance and metabolic dysfunction than total
adiponectin [23].
In vitro, total adiponectin has been shown to act on
specific receptors to increase apoptosis [24] and inhibit
leptin-induced proliferation in oesophageal AC cell lines
[20]. The expression of adiponectin receptors have also
been shown to be reduced in Barrett's oesophagus epithe-
lium at the mRNA level [24]. Low levels of total adi-
ponectin have been associated with Barrett's oesophagus
[25], oesophageal AC [26], and a range of other obesity-
related cancers [27].
Systemic Inflammation
Individuals with Barrett's oesophagus also exhibit signs of
chronic inflammation indicated by higher circulating lev-
els of inflammatory mediators such as IL-6 [28,29] and
TNF-α [30]. The protein expression of TNF-α is also
notably elevated in Barrett's oesophagus tissue samples
and even more so in AC tissue [31]. Additionally, TNF-α
has been shown to stimulate the proliferation of oesopha-
geal AC cell lines in vitro [31]. Further evidence of a link
between inflammation and oesophageal AC comes from
findings that weekly users of aspirin had a 50% reduction
in oesophageal AC risk [32-34].
Insulin Resistance
Because insulin has a range of actions (mitogenic and
anti-apoptotic) in addition to its effect on blood glucose
concentrations, it has been postulated that hyperinsuli-
naemia (secondary to insulin resistance) may also drive
proliferative and metaplastic changes in gastrointestinal
mucosa [35]. Furthermore, elevated levels of leptin and
inflammatory mediators such as TNF-α, are also charac-
teristics of an insulin-resistant state [36].
Exercise may Modulate Oesophageal Cancer Risk
Due to the increasing incidence and very high mortality
associated with oesophageal AC, interventions effective
in preventing the neoplastic progression of Barrett's
oesophagus are urgently needed. Although limited, there
are some epidemiological data to suggest that exercise
may modulate oesophageal AC risk. Data from one large
cohort study suggests that ≥ 100 minutes of physical
activity per week (measured by self report), compared to
no physical activity is associated with a significant 32%
reduction in AC risk, although this association was atten-
uated when further adjustment was made for BMI [37].
Higher levels of self reported occupational physical activ-
Figure 1 The Barrett's metaplasia-dysplasia-adenocarcinoma sequence.
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ity before the age of 65 have also been associated with a
39% decreased risk of oesophageal AC in one population-
based case-control study [38].
Physical activity may act to modulate oesophageal AC
risk by reversing the metabolic aberrations associated
with Barrett's oesophagus and oesophageal AC. Evidence
from clinical trials in overweight individuals without Bar-
rett's oesophagus, suggests that physical activity can sig-
nificantly reduce leptin concentrations with [39-41] and
without [42-44] accompanying exercise induced weight-
loss. Beneficial increases in adiponectin have also been
observed following 4 weeks of exercise, with results
remaining significant after adjusting for body weight,
body fat and plasma insulin [45]. Furthermore, physical
activity is considered to play an integral role in the treat-
ment and prevention of insulin resistance [46] and has
anti-inflammatory effects [47,48] which may also benefit
Barrett's oesophagus patients. Finally, exercise may lead
to reductions in centrally stored body fat which may sub-
sequently reduce gastro-oesophageal reflux symptoms,
contributing further to reductions in oesophageal AC
risk.
Overall, preliminary data from epidemiological studies
and evidence from clinical trials in overweight popula-
tions provide a strong rationale for trialing physical activ-
ity interventions in patients with Barrett's oesophagus to
reduce cancer risk. T o date no clinical trials have tested
the hypothesis that physical activity reduces oesophageal
AC risk factors in males with Barrett's oesophagus.
The aim of the "Exercise and the Prevention of Oesoph-
ageal Cancer" (EPOC) study is to determine the effect of a
24 week moderate-intensity exercise intervention versus
stretching on biomarkers associated with oesophageal
AC development in overweight or obese, inactive males
with Barrett's oesophagus. Our primary outcomes are
serum concentrations of leptin, adiponectin, TNF-α, C-
reactive protein (CRP), IL-6 and insulin resistance. Sec-
ondary outcomes include body composition, gastro-
oesophageal reflux symptoms, cardiovascular fitness and
muscular strength.
Methods/Design
EPOC is a randomized controlled trial with participants
randomized into a 24-week exercise intervention arm or
a control arm (Figure 2). All outcomes will be measured
by study personnel blinded to participants' group alloca-
tion. The study is being conducted in Brisbane, Australia.
The protocol has been approved by The University of
Queensland Human Ethics Committee, and the Human
Ethics Committees of the four participating hospitals -
Royal Brisbane & Women's Hospital, Princess Alexandra
Hospital, Prince Charles Hospital and The Wesley Hospi-
tal.
Participants
This study is aiming to recruit 80 males with Barrett's
oesophagus. Barrett's oesophagus is defined as the abnor-
mal appearance of the lining of the distal oesophagus
Table 1: Biomarkers associated with the progression of Barrett's oesophagus to oesophageal adenocarcinoma.
Biomarker Direction Putative mechanism of promoting oesophageal 
adenocarcinoma
Gastro-oesophageal reflux frequency and severity Increased Chronic inflammation and damage to oesophageal epithelium
Central obesity Increased Systemic metabolic dysfunction
Increased reflux of gastric acid into the lower oesophagus via 
increased intra-abdominal pressure and/or hiatus hernia
Leptin Increased Mitogenic
Angiogenic
Anti-apoptotic
Adiponectin Decreased Increased insulin resistance
Pro-inflammatory
Anti-apoptotic
Inflammatory mediators: Increased Mitogenic
Angiogenic
C-reactive protein Increased differentiation
Tumour necrosis factor-α Anti-apoptotic
Interleukin-6 Decreased DNA repair
Insulin Increased Mitogenic
Anti-apoptotic
Increased leptin
Increased tumour necrosis factor-α
Decreased adiponectinWinzer et al. BMC Cancer 2010, 10:292
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(determined via endoscopy) in addition to histological
evidence of intestinal metaplasia (determined via biopsy)
[49]. Both newly diagnosed and prevalent cases of Bar-
rett's oesophagus will be included. The study is limited to
males only as males are twice as likely to develop oesoph-
ageal AC than females [50]. Participants must be English
speaking, residing in greater Brisbane, aged 18-70 years,
have a BMI between 25 kg/m2 and 34.99 kg/m2 and be
performing ≤ 60 minutes per week of moderate-vigorous
intensity exercise during the previous 6 weeks. Addition-
ally, participants must not have gained or lost ≥ 5 kg of
body weight during the past 6 months. Exclusion criteria
include cardiac, respiratory, renal, liver, neurological or
inflammatory disease. Individuals with diabetes mellitus,
hypertension, hypotension, a cancer diagnosis within 5
years or orthopaedic injuries limiting exercise participa-
tion, will also be excluded.
Recruitment
Participants will be identified and recruited through gas-
troenterology department appointments, hospital data-
bases and a research study database. Recruitment will
take place over a period of 15 months (May 2009 - August
2010). Patients attending appointments at the gastroen-
terology departments of three large tertiary hospitals, one
private hospital and a private gastroenterology clinic in
Brisbane, Australia, are provided with an information
sheet by their treating doctor and given an expression of
interest form to complete. Potential participants identi-
fied by hospital personnel from hospital databases will be
posted a letter and an expression of interest form. Poten-
tial participants who have expressed interest in joining
the study will then be contacted by telephone by study
personnel to have the study explained and be screened for
eligibility. Participants will enter the study once written
informed consent has been obtained.
Randomization
Participants are allocated to the intervention arm or the
control arm via computerised randomization http://
www.randomization.com, following completion of base-
line assessment. The randomization sequence was gener-
ated by a research assistant not involved with the study.
Figure 2 CONSORT diagram.
Baseline testing 
Randomization
Midpoint outcome 
measures (week 12)
Research facility 
database X 1 Private hospital
Exercise
(Intervention Arm)
Stretching 
(Control Arm)
Assess for eligibility
Private endoscopy 
clinic
X 3 Public 
hospitals
Midpoint outcome 
measures (week 12)
Endpoint outcome 
measures (week 24)
Endpoint outcome 
measures (week 24)Winzer et al. BMC Cancer 2010, 10:292
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Group allocation is concealed from investigators using
sealed, numbered envelopes.
Intervention Arm
Participants randomized to the intervention arm of the
study undertake 60 minutes of exercise, five days per
week for 24 weeks. Each session involves: 30 minutes of
moderate-intensity aerobic training (60-70% of maximum
heart rate) and 30 minutes of resistance training (plus a 5
minute warm-up and cool-down of light intensity). Par-
ticipants perform one exercise session per week at a hos-
pital gymnasium in small groups under the supervision of
study personnel (physiotherapist/exercise physiologist).
In addition, each participant is provided with a free gym
membership to complete another four exercise sessions
independently at a privately run health club in their local
area.
Participants perform aerobic exercise on treadmills,
cycling or rowing stationary ergometers and elliptical
machines. During the sessions exercise intensity is mea-
sured via the unmodified (6-20) BORG scale. Participants
are instructed to maintain their rate of perceived exertion
between "somewhat hard" and "hard" (13-15) [51]. The
resistance component consists of performing one set of
12-15 repetitions during weeks 0-8; and two sets of 8-10
repetitions during weeks 9-24. Resistance is prescribed to
achieve muscular fatigue between 8-15 repetitions
depending on the training phase. Exercises include: chest
press, leg press, shoulder press, seated row, lunges,
assisted chin up, assisted dip and core stability.
The program is consistent with the current World Can-
cer Research Fund and American Institute for Cancer
Research recommendations for cancer prevention which
advocate 30-60 minutes of moderate-intensity exercise
on most if not all days of the week [10].
Control Arm
Participants allocated to the control arm attend a hospital
gymnasium once a week to perform 45 minutes of
stretching in small groups under the supervision of study
personnel. They are also instructed to perform the
stretching program independently at home, four times
per week. Stretching will act as an 'attention' control con-
dition. Participants in the control arm are instructed not
to commence a new exercise program during the study.
At the conclusion of the study they are offered an exercise
program and a complimentary three month gym mem-
bership to a private health club in their local area.
Attendance and Adherence
Participants document the details of their independent
exercise or stretching sessions daily in a physical activity
diary. For participants in the intervention arm, atten-
dance at the private health club is also electronically
recorded each time they visit via their membership card.
Secondary outcome measures such as cardiovascular fit-
ness, muscular strength and body composition will also
provide information regarding adherence to the protocol.
Primary Outcomes
All primary outcomes are measured at baseline (week 0),
midpoint (week 12) and at the conclusion of the interven-
tion (week 24). Biomarkers associated with oesophageal
AC development will be measured as primary outcomes
via blood samples. Fasting blood samples of 30 ml will be
obtained by blood collectors from an accredited pathol-
ogy laboratory from the antecubital vein between 08:00-
10:00 am and at least 24 hours post exercise to minimize
diurnal fluctuations and acute exercise effects. Blood
samples will be centrifuged within 20 minutes of collec-
tion and stored at -80°C. Laboratory personnel will anal-
yse the samples in two batches over a period of 24
months.
Serum leptin will be analysed via radioimmunoassay
(RIA) (Linco Research, Missouri, USA) and serum adi-
ponectin (total and HMW) by an enzyme-linked immu-
nosorbent assay (ELISA) (Linco Research, Missouri,
USA). The inter- and intra-assay coefficients of variation
(CV) are < 8% for leptin and < 9% for adiponectin.
Fasting serum insulin will be analysed using an immu-
noenzymatic 'sandwich' assay via an ACCESS system
(Beckman Coulter, Fullerton, USA) and plasma glucose
concentrations determined with an oxygen rate method
via the SYNCHRON system (Beckman Coulter, Fullerton,
USA) with an inter- and intra-assay CV of < 5% for both
insulin and glucose. Insulin resistance will be calculated
using the reciprocal index of homeostasis model assess-
ment (HOMA-IR) [52] and the Quantitative Insulin Sen-
sitivity Check Index (QUICKI) [53]. Both measures
calculate ratios of fasting insulin:glucose concentrations
using different algorithms and have been shown to be
reproducible and valid measures of insulin resistance.
Serum concentrations of CRP will be analysed using a
high sensitivity Near Infrared Particle Immunoassay with
the SYNCHRON system (Beckman Coulter, Fullerton,
USA). Inter- and intra-assay CV is < 5%. IL-6 will be mea-
sured in serum with the Immulite 2000 analyser using an
immunometric assay (Siemens, USA) with an inter- and
intra-assay CV of < 7%. Serum TNF-α will be measured
using a Bio-Plex suspension array system via immunoas-
say (Bio-Rad laboratories, Hercules, USA), with inter-
assay CV of < 8% and intra-assay CV of < 6%.
Secondary Outcomes
Secondary outcomes will also be measured at week 0, 12
and 24.
Body Composition
Body fat and fat free mass will be measured in triplicate
using bioimpedance spectroscopy (ImpediMed SFB7,Winzer et al. BMC Cancer 2010, 10:292
http://www.biomedcentral.com/1471-2407/10/292
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ImpediMed Ltd., Australia). Typical coefficients of varia-
tion within a measurement session range from 0.3 to 3.0%
[54]. Waist circumference will be calculated in duplicate
at the midpoint between the lower costal (rib) border and
the iliac crest. Hip circumference will be measured in
duplicate as the maximum diameter at the greater tro-
chanter. Waist-to-hip ratio will also be determined.
BMI will be calculated (weight [kg]/height [m]2) as it is
a reasonable measure of global adiposity. Height is mea-
sured using a stadiometer to 1 mm, without shoes, arms
by side and heels together. Weight is measured to the
nearest 0.1 kg in light clothing, without shoes, on a cali-
brated scale (UC-321, A&D Co. Ltd., Japan) with an
empty bladder.
Cardiovascular Fitness
Cardiovascular fitness will be estimated using peak oxy-
gen uptake (VO2peak) during the Modified Shuttle Walk
Test [55]. VO2peak will be measured using a Cortex Meta-
max 3 portable metabolic analyser (Cortex:biophysik,
GMbH, Germany) during the test. VO2peak is the highest
oxygen uptake achieved with an increasing external work
rate, but unlike VO2max, a plateau in oxygen uptake may
not be observed. VO2peak is a useful estimation of cardio-
vascular fitness as not every participant may reach
VO2max before symptom limitation occurs [56].
Muscle Strength
One-repetition maximum (1 RM) tests will be performed
on the bench press and leg press to measure muscle
strength. 1 RM is the maximum weight a person can lift
only one time with correct technique. 1 RM has shown to
be a reliable and valid measure of strength in middle
aged, untrained adults [57].
Gastro-oesophageal Reflux Disease
T here is no gold standard test to diagnose or monitor
gastro-oesophageal reflux disease [58]. Gastro-oesopha-
geal reflux symptoms will be measured using the Gastro-
esophageal Reflux Disease Impact Scale (GIS) which is
short and simple to use; responsive to change over time;
completed by patients and has documented internal con-
sistency, reproducibility and construct validity [59].
Monitoring Confounding Variables
Participants will document medication use and all proto-
col and non-protocol exercise performed in a daily log;
smoking habits will also be recorded every 4 weeks. The
International Physical Activity Questionnaire (IPAQ),
(long, last 7 days, self-administered format) [60,61] will
also be completed by participants at week 0, 12 and 24
and will provide additional information regarding inci-
dental, job and leisure time physical activity; and sitting
time over a one week period. All participants will be
instructed to maintain a consistent diet throughout the
study and this will be evaluated via a Food Frequency
Questionnaire completed at week 0, 12 and 24.
Sample Size Calculation
There is limited evidence on which to base the minimum
detectable difference for the sample size calculation.
Namely, the magnitude of change in the primary bio-
marker outcomes that is associated with a reduction in
oesophageal AC risk is not known. A minimum differ-
ence of 10% between the means of the intervention arm
and the control arm for all primary outcomes is likely to
produce a clinical benefit and is achievable by the inter-
vention. Standard deviations were based on those
observed in previous clinical trials investigating the effect
of exercise on overweight or obese, inactive, healthy
males. Thus, a sample size of 40 participants per group
(80 in total) is needed to detect a minimal difference of
10% in primary outcomes between groups, with 80%
power, a type I error of 5% and allowing for 10% attrition
(two-tailed).
Statistical Analysis
Generalised linear models, estimating variance appropri-
ately for repeated measures, will be used to determine
whether there are differences between the exercise inter-
vention group and the control group in primary and sec-
ondary outcomes. Models will be adjusted for baseline
outcome values, to account for regression to the mean, as
well as the main effects of group, time and their interac-
tion. Mediation and moderation of intervention effects
will be examined with change in body weight, body fat,
minutes exercised per week and VO2peak considered a pri-
ori to be of potential interest. Analyses will be performed
using intention-to-treat principles and on a per-protocol
basis. Statistical significance will be set at p < 0.05 (two-
tailed).
Discussion
The EPOC study aims to determine whether exercise can
modulate the biochemical pathways to oesophageal can-
cer development in males with the pre-malignant condi-
tion Barrett's oesophagus. Exercise may prove to be an
effective intervention in reducing the risk of oesophageal
AC development which would have important health
implications for males with Barrett's oesophagus.
Moreover, findings from the EPOC study will help to
further define the role of exercise in the primary preven-
tion of cancer by adding to the limited number of clinical
trials of exercise interventions and cancer-related bio-
markers [62-71]. As participants targeted by the EPOC
study may be at an even higher cancer risk than those
previously studied, greater exercise intervention effects
may be observed. Lastly, the biological mechanisms
underlying the inverse association between physical
activity and carcinogenesis can be further explored.
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